2 Results

Sort by: Published date Updated Date Title ID Descending Ascending

A Predictive Marker and Treatment to Sensitize Multiple Myeloma Patients to Venetoclax (ABT-199) Application A marker that predicts Venetoclax (ABT-199) sensitivity that can also be targeted with a drug to help multiple myeloma patients. Key Benefits Marker that predicts if venetoclax will be an effective treatment in multiple myeloma patients. A drug that targets venetoclax resistant multiple myeloma cells to improve treatment in patients. Market... Published: 7/28/2023       Contributor(s): Malathy (mala) Shanmugam, Richa Bajpai

Combination Therapy for Increasing Venetoclax Sensitivity in Multiple Myeloma Application Marker and co-therapy that inhibits succinate dehydrogenase to increase patient response to venetoclax. Key Benefits Co-therapy increases MM sensitivity to venetoclax treatment. Identifies patients who will respond to venetoclax therapy. Market Summary Multiple Myeloma (MM) is a cancer of plasma cells responsible for making antibody... Published: 12/1/2023       Contributor(s): Malathy (mala) Shanmugam, Richa Bajpai